Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7301 - 7325 of 8035 in total
Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.
Investigational
Matched Description: … stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
Investigational
Matched Description: … JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination …
CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.
Investigational
Matched Description: … 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
Matched Description: … VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of
XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and...
Investigational
Matched Description: … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth ... growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
Matched Description: … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct ... On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its …
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF). The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2...
Investigational
Matched Description: … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with ... As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252 …
NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … The product is intended for basal insulin treatment of diabetes mellitus. …
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, …
SPI-1620 is an endothelin B receptor agonist. In animal models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of anticancer agents to the tumor. It is being developed as an adjunct to chemotherapy.
Investigational
Matched Description: … models SPI-1620 selectively and transiently increases tumor blood flow allowing increased delivery of
Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia).
Investigational
Matched Description: … trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of
Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment).
Investigational
Matched Description: … Azintuxizumab vedotin is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and …
TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin).
Investigational
Matched Description: … Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of
VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.
Investigational
Matched Description: … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases …
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
Investigational
Matched Description: … This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune …
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action …
RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.
Investigational
Matched Description: … 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of
Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Vet approved
Matched Description: … Tricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of
Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.
Investigational
Matched Description: … Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer …
S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others.
Investigational
Matched Description: … S-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung …
Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .
Experimental
Matched Description: … Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of
EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.
Investigational
Matched Description: … EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of
RPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.
Investigational
Matched Description: … developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of
Displaying drugs 7301 - 7325 of 8035 in total